Aldeyra Therapeutics, Inc.
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||||
| – | 4.6 | 3.4 | 3.5 | 5.6 | 4.7 | 4.5 | 4.9 | 8.9 | 27.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 527.7 | 499.4 | 499.4 | 818.8 | 1,216.3 | 1,420.5 | 933.1 | 1,278.6 | – | – | – | |
| 3.8 | 3.4 | 2.5 | 3.0 | 2.4 | 3.3 | 4.0 | 4.3 | 10.1 | 2.6 | 3.1 | 2.4 | 2.8 | 3.5 | 1.7 | 2.4 | 4.0 | 4.5 | 4.3 | 2.6 | 2.3 | 1.1 | 1.3 | 1.3 | 1.9 | 2.7 | 4.2 | 3.8 | 3.2 | 1.7 | 1.7 | 2.0 | 3.8 | 4.2 | 5.5 | 4.1 | 6.3 | 7.1 | 2.4 | 3.3 | |
| – | 4.0 | 2.5 | 2.9 | 4.0 | 4.0 | 3.9 | 4.2 | 8.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 203.1 | 277.7 | 357.9 | 684.8 | 1,055.9 | 1,277.4 | 827.5 | 1,099.2 | – | – | – | |
| -14.5% | -20.3% | -21.5% | -23.8% | -16.1% | -14.6% | -15.9% | -15.3% | -9.4% | -13.4% | -14.2% | -25.4% | -29.1% | -26.6% | -65.3% | -33.6% | -14.4% | -14.0% | -6.6% | -6.0% | -7.7% | -18.3% | -16.4% | -22.7% | -18.4% | -13.8% | -9.1% | -9.4% | -10.6% | -14.6% | -15.7% | -15.7% | -9.5% | -14.5% | -13.2% | -18.0% | -12.8% | -10.7% | -25.3% | -17.4% | |
| Margins | ||||||||||||||||||||||||||||||||||||||||
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -66.9% | -65.3% | -64.6% | -64.1% | -102.1% | -102.2% | -102.5% | -102.7% | – | – | – | |
| – | -116.0% | -93.5% | -98.7% | -99.8% | -79.9% | -79.8% | -91.7% | -110.0% | -478.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -10,899.6% | -9,012.4% | -10,964.8% | -12,642.5% | -24,585.1% | -25,007.8% | -21,802.0% | -18,474.6% | – | – | – | |
| – | -116.0% | -93.5% | -98.5% | -99.6% | -79.4% | -79.1% | -90.6% | -108.6% | -468.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -9,562.0% | -7,643.3% | -9,645.3% | -11,409.4% | -22,840.7% | -23,596.2% | -20,700.7% | -17,664.3% | – | – | – | |
| – | -94.0% | -73.8% | -84.0% | -90.0% | -68.4% | -71.4% | -74.4% | -83.8% | -362.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7,724.0% | -7,858.7% | -7,824.7% | -7,812.0% | -17,670.4% | -18,691.6% | -16,782.1% | -16,392.2% | – | – | – | |
| Returns | ||||||||||||||||||||||||||||||||||||||||
| -71.7% | -86.4% | -67.2% | -84.9% | -43.7% | -56.4% | -71.2% | -79.5% | -123.2% | -44.9% | -58.8% | -74.8% | -114.6% | -126.5% | -126.7% | -93.3% | -57.0% | -63.1% | -30.9% | -19.9% | -24.3% | -28.1% | -33.2% | -38.0% | -40.0% | -41.1% | -44.3% | -40.1% | -37.1% | -31.3% | -26.5% | -38.5% | -52.6% | -78.7% | -90.7% | -91.6% | -87.7% | -76.5% | -64.9% | -60.8% | |
| -63.0% | -74.2% | -59.7% | -74.9% | -40.7% | -50.6% | -62.9% | -67.9% | -94.8% | -40.9% | -52.3% | -68.3% | -75.3% | -80.5% | -87.4% | -68.8% | -44.6% | -45.1% | -26.5% | -18.1% | -21.6% | -24.8% | -28.4% | -32.9% | -34.2% | -34.2% | -36.2% | -33.5% | -31.0% | -25.3% | -21.2% | -30.0% | -38.2% | -53.4% | -61.9% | -59.6% | -55.5% | -47.0% | -41.2% | -48.5% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||||
| -13 | -11 | -18 | -13 | -32 | -19 | -20 | -23 | -17 | – | -44 | -39 | -37 | -30 | -24 | -46 | -71 | -63 | -123 | -234 | -226 | -214 | -143 | -105 | -113 | -128 | -149 | -136 | -127 | -127 | -87 | -56 | -53 | -39 | -35 | -26 | -44 | -55 | -49 | -45 | |
| 87.9% | 86.0% | 88.8% | 88.2% | 93.2% | 89.6% | 88.3% | 85.4% | 77.0% | 91.1% | 89.1% | 91.2% | 65.7% | 63.7% | 69.0% | 73.7% | 78.3% | 71.4% | 85.6% | 91.1% | 88.9% | 88.2% | 85.6% | 86.6% | 85.5% | 83.3% | 81.6% | 83.5% | 83.5% | 80.8% | 80.3% | 78.0% | 72.5% | 67.9% | 68.2% | 65.1% | 63.3% | 61.4% | 63.4% | 79.7% | |
| 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.0 | |
| Per Share | ||||||||||||||||||||||||||||||||||||||||
| -1.48 | -1.36 | -1.36 | -1.31 | -1.29 | -1.15 | -1.32 | -1.49 | -1.68 | -1.44 | -1.70 | -1.87 | -2.15 | -2.08 | -1.89 | -1.64 | -1.04 | -0.97 | -0.85 | -0.85 | -0.92 | -1.00 | -1.09 | -1.13 | -1.11 | -1.06 | -1.04 | -0.89 | -0.77 | -0.63 | -0.51 | -0.64 | -0.75 | -0.94 | -0.96 | -0.84 | -0.72 | -0.56 | -0.45 | -0.38 | |
| -0.02 | 1.17 | 1.46 | 1.33 | 1.29 | 1.45 | 1.67 | 1.64 | 1.55 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 2.06 | 1.57 | 2.03 | 1.54 | 2.95 | 2.04 | 1.86 | 1.87 | 1.36 | 3.20 | 2.90 | 2.50 | 1.88 | 1.65 | 1.49 | 1.75 | 1.83 | 1.54 | 2.76 | 4.31 | 3.79 | 3.55 | 3.27 | 2.99 | 2.77 | 2.58 | 2.33 | 2.21 | 2.09 | 2.02 | 1.91 | 1.65 | 1.43 | 1.19 | 1.06 | 0.92 | 0.82 | 0.74 | 0.70 | 0.63 | |
| -1.13 | -1.10 | -1.08 | -1.12 | -1.16 | -0.99 | -1.19 | -1.22 | -1.30 | -1.11 | -1.28 | -1.53 | -1.54 | -1.54 | -1.63 | -1.41 | -1.07 | -0.97 | -0.78 | -0.68 | -0.68 | -0.73 | -0.72 | -0.91 | -0.98 | -0.97 | -0.91 | -0.79 | -0.71 | -0.51 | -0.52 | -0.52 | -0.52 | -0.73 | -0.76 | -0.68 | -0.67 | -0.55 | -0.43 | -0.37 | |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.